AlectorALEC
Market Cap: $543M
About: Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Employees: 245
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
341% more call options, than puts
Call options by funds: $300K | Put options by funds: $68K
16% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 50
15% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 20
2% more funds holding
Funds holding: 155 [Q1] → 158 (+3) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
5.38% less ownership
Funds ownership: 80.78% [Q1] → 75.39% (-5.38%) [Q2]
29% less capital invested
Capital invested by funds: $466M [Q1] → $330M (-$136M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Andrew Fein 39% 1-year accuracy 46 / 118 met price target | 527%upside $35 | Buy Reiterated | 20 Jun 2024 |